(Q34549230)

English

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience (English)

1 reference

Europe PubMed Central

3 August 2017

stem cell transplantation

1 reference

based on heuristic

inferred from title

12

object named as

Barbara Pro

1 reference

Europe PubMed Central

3 August 2017

14

object named as

Luis Fayad

0 references

17

object named as

Mark F Munsell

1 reference

Europe PubMed Central

3 August 2017

7

object named as

Chitra Hosing

1 reference

Europe PubMed Central

3 August 2017

2

object named as

Rima Saliba

1 reference

Europe PubMed Central

3 August 2017

Richard E Champlin

18

object named as

Richard E Champlin

1 reference

Europe PubMed Central

3 August 2017

4

object named as

Sergio A Giralt

1 reference

Europe PubMed Central

3 August 2017

8

object named as

Issa F Khouri

1 reference

Europe PubMed Central

3 August 2017

Muzaffar Qazilbash

11

object named as

Muzaffar H Qazilbash

1 reference

Europe PubMed Central

3 August 2017

Sandra A Acholonu

3

object named as

Sandra Acholonu

1 reference

Europe PubMed Central

3 August 2017

Jorge Romaguera

13

object named as

Jorge Romaguera

1 reference

Europe PubMed Central

3 August 2017

Fredrick B Hagemeister

15

object named as

Frederick Hagemeister

1 reference

Europe PubMed Central

3 August 2017

16

object named as

Anas Younes

1 reference

Europe PubMed Central

3 August 2017

author name string

Paolo Anderlini

1

1 reference

Europe PubMed Central

3 August 2017

Borje Andersson

5

1 reference

Europe PubMed Central

3 August 2017

Naoto T Ueno

6

1 reference

Europe PubMed Central

3 August 2017

Daniel Couriel

9

1 reference

Europe PubMed Central

3 August 2017

Marcos de Lima

10

1 reference

Europe PubMed Central

3 August 2017

publication date

26 January 2008

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

93

1 reference

Europe PubMed Central

3 August 2017

2

1 reference

Europe PubMed Central

3 August 2017

257-264

1 reference

Europe PubMed Central

3 August 2017

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

7 July 2018

Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

7 July 2018

Reduced-intensity allogeneic stem cell transplantation in adults and children with malignant and nonmalignant diseases: end of the beginning and future challenges

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

7 July 2018

How and when should we monitor chimerism after allogeneic stem cell transplantation?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

7 July 2018

'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

7 July 2018

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

7 July 2018

Autologous hematopoietic cell transplantation in Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

7 July 2018

High-dose therapy for Hodgkin's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

7 July 2018

Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

7 July 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

7 July 2018

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

27 October 2018

Therapies for relapsed Hodgkin lymphoma: transplant and non-transplant approaches including immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

27 October 2018

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

27 October 2018

Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

27 October 2018

Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

27 October 2018

Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

27 October 2018

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4238917

27 October 2018

Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors

1 reference

https://pubmed.ncbi.nlm.nih.gov/18223284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18223284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

1 reference

https://pubmed.ncbi.nlm.nih.gov/18223284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18223284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of refractory and relapsed Hodgkin's lymphoma: facts and perspectives

1 reference

https://pubmed.ncbi.nlm.nih.gov/18223284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of DNA restriction fragment length polymorphisms to document marrow engraftment and mixed hematopoietic chimerism following bone marrow transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18223284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term results of blood and marrow transplantation for Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/18223284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/18223284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response

1 reference

https://pubmed.ncbi.nlm.nih.gov/18223284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

1 reference

https://pubmed.ncbi.nlm.nih.gov/18223284

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.11828

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34549230&oldid=2138091794"